References
- National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma expert panel. Report 2. Bethesda, Md: US Dept of Health and Human Services, 1997. NIH publication 97–4051
- D'Alonzo GE, Steinijans VW, Keller A. Measurements of morning and evening airflow grossly underestimate the circadian variability of FEV1 and peak expiratory flow rate in asthma. Am J Respir Crit Care Med 1995; 152(3): 1097–9
- Gannon PF, Newton DT, Pantin CF, et al. Effect of the number of peak expiratory flow readings per day on the estimation of diurnal variation. Thorax 1998; 53(9): 790–2
- Goldstein MF, Veza BA, Dunsky EH, et al. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV1 responses, and methacholine inhalation challenges in the evaluation of suspected asthma. Chest 2001; 119(4): 1001–10
- Gibson PG, Wlodarczyk J, Hensley MJ, et al. Using quality-control analysis of peak expiratory flow recordings to guide therapy for asthma. Ann Intern Med 1995; 123(7): 488–92
- Kunzli N, Stutz EZ, Perruchoud AP, et al. Peak flow variability in the SAPALDIA study and its validity in screening for asthma-related conditions. The SAPALDIA Team. Am J Respir Crit Care Med 1999; 160(2): 427–34
- Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335(12): 841–7
- Clough JB, Holgate ST. Episodes of respiratory morbidity in children with cough and wheeze. Am J Respir Crit Care Med 1994; 150(1): 48–53
- Doull IJ, Lampe FC, Smith S, et al. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial. Br Med J 1997; 315(7112): 858–62
- Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332(3): 133–8
- Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343(15): 1054–63
- Pauwels, RA, Pedersen S, Busse WW, et al, for the START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomized, double-blind trial. Lancet 2003; 361 (9363): 1066–7
- British guideline on the management of asthma. Thorax 2003; 58(Suppl 1): il–83
- Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178(5): 223–5
- Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331(11): 700–5
- Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 412(3 Suppl): Sl–40
- O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164(8 Pt 1): 1392–7
- Tattersfield AE, Lofdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357(9252): 257–61
- Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22(5):787–94
- Jenkins C. Formoterol as relief medication in asthma: the jury is still out. Eur Respir J 2003; 22(5): 723–4
- US Food and Drug Administration. FDA Talk Paper. Labeling changes for drug products that contain salmeterol. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01248.html. Accessed Mar 3, 2004
- Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999; 160(6): 1862–8
- Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br Med J 2003; 326(7390): 621–5